CDK4/6 Inhibitors for Advanced Hormone Receptor–Positive Breast Cancer, 2019 and Beyond

Layman, Rachel M.

doi:10.6004/jnccn.2018.7271

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intrinsic or subsequently acquired resistance to endocrine therapy continues to be a major obstacle in the therapy for hormone receptorpositive BC (Szostakowska, Trebinska-Stryjewska, Grzybowska, & Fabisiewicz, 2019). Although current treatment that targets the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin and cyclin D/cyclin-dependent kinases 4 and 6 signaling pathways, usually in combination with aromatase inhibitors or fulvestrant, have markedly improved the survival of this subset of patients (Araki & Miyoshi, 2018;Layman, 2019), it remains imperative to identify novel potent modulators that regulate the cellular response to endocrine therapy in BC. Herein, through conducting an in-depth analysis of datasets derived from the GEO database, we found that SOX11 was differentially expressed in BC cases in different recurrence scenarios treated with tamoxifen.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial‐to‐mesenchymal transition via slug in MCF‐7 breast cancer cells

Xiao

Xie

Qin

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Resistance to tamoxifen remains a prominent conundrum in the therapy of hormone‐sensitive breast cancer. Also, the molecular underpinnings leading to tamoxifen resistance remain unclear. In the present study, we utilized the Gene Expression Omnibus database to identify that SOX11 might exert a pivotal function in conferring tamoxifen resistance of breast cancer. SOX11 was found to be markedly upregulated at both the messenger RNA and protein levels in established MCF‐7‐Tam‐R cells compared to the parental counterparts. Moreover, SOX11 was able to activate the transcription of slug via binding to its promoter, resulting in promoting the progress of epithelial‐to‐mesenchymal transition and suppressing the expression of ESR1. Downregulating SOX11 expression can restore the sensitivity to 4‐hydroxytamoxifen in MCF‐7‐Tam‐R cells. Survival analysis from large sample datasets indicated that SOX11 was closely related to poorer survival in patients with breast cancer. These findings suggest a novel feature of SOX11 in contributing to tamoxifen resistance. Hence, targeting SOX11 could be a potential therapeutic strategy to tackle tamoxifen resistance in breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial‐to‐mesenchymal transition via slug in MCF‐7 breast cancer cells

Xiao

Xie

Qin

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Nonhormonal-based therapies that rely on chemotherapeutic agents may also be indicated in certain circumstances for recurrent or stage IV mBC, including poly (ADP-ribose) polymerase (PARP) inhibitors ( Layman, 2019 ).…”

Section: Treatment Options For Hr+/her2− Postmenopausal Metastatic Brmentioning

confidence: 99%

Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence

Gillespie¹

2020

JADPRO

View full text Add to dashboard Cite

Hormone receptor positivity and early stage diagnosis are generally considered signs of good prognosis in breast cancer. However, breast cancer all too frequently can become resistant to hormone-based therapies, and women can experience recurrence of their breast cancer decades after the diagnosis of early stage disease. To address the therapeutic needs for advanced and metastatic hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2−) breast cancer, a number of new drugs have been tested and approved for this indication, including the class of drugs that works as cyclin-dependent kinase (CDK) 4/6 inhibitors. These drugs, often combined with other hormone-based therapy, have demonstrated considerable success in clinical trials and are now being used widely in oncology practices. Because all of the currently approved CDK4/6 inhibitor agents (palbociclib, ribociclib, and abemaciclib) are given orally, issues of patient comprehension of and adherence to prescribed regimens should be at the forefront of practitioners’ concerns about these drugs. In addition, ways to support and facilitate decision-making by patients related to this class of agents and other therapies recently approved for the same indication require focused attention by health-care providers. Oncology has continued to move toward a more patient-specific, precision medicine approach. Likewise, advanced practitioners have the opportunity to identify patient characteristics, preferences, and needs that are unique to individual patients to enhance precision treatment.

show abstract

Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer

Zhang

Wang

et al. 2019

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

CDK4/6 Inhibitors for Advanced Hormone Receptor–Positive Breast Cancer, 2019 and Beyond

Cited by 3 publications

References 6 publications

Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial‐to‐mesenchymal transition via slug in MCF‐7 breast cancer cells

Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial‐to‐mesenchymal transition via slug in MCF‐7 breast cancer cells

Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence

Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer

Contact Info

Product

Resources

About